Bristol-Myers Squibb Co. and Lonza have entered a multi-year expansion of their existing biologics manufacturing agreement to include the production of commercial quantities of a second BMS biologic at Lonza’s mammalian manufacturing facility in Portsmouth, NH. Financial terms were not disclosed.
 
The companies have been collaborating since 2003 to produce commercial supplies of BMS biologics worldwide. Lonza also currently produces clinical supplies of an investigational biologic for BMS.
 
“Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities,” said Lou Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb.
 
“We are pleased to extend our relationship with Bristol-Myers Squibb for the commercial production of their innovative drug substance, said Marc Funk, chief operating officer of Lonza’s Pharma & Biotech Segment. “This reinforces Lonza’s mission to support life-saving medicines by being a reliable supplier of drug substance for our customers with high-quality commercial GMP manufacturing services delivered to the market.”
 
Lonza’s development and manufacturing facilities offer expression systems and platform processes for scale-up throughout the clinical pipeline. In addition to its Portsmouth facility, Lonza has three additional clinical-to-commercial mammalian production facilities in Tuas, Singapore; Porrino, Spain; and Slough, UK.